Our Pipeline
At Qualthera Pharmaceuticals, we build smarter, faster pipelines by focusing on compounds with established safety profiles and overlooked therapeutic potential. Instead of chasing new molecules, we re-engineer existing ones to address today’s most pressing medical needs—working to reduce timelines and risk while maximizing impact.
Learn More
Discover how we're transforming proven compounds into next-generation therapies—without the long delays and high risks of traditional drug development.
Our Drug Development Pipeline
Repurposing Medicine. Redefining Access.
CBD Implant – Chronic Pain & Neurodegenerative Disorders
Our lead candidate is a biodegradable CBD implant designed to deliver consistent, long-acting therapeutic exposure. This patent-pending platform addresses the absorption and variability issues of oral and topical CBD—making it a promising approach for chronic pain, Alzheimer’s, and Parkinson’s disease. We aim to bring the first FDA-approved CBD implant to market, offering a scalable solution where current options may fall short.
ALS Program
We are evaluating a repurposed combination of compounds for its potential use in treating Amyotrophic Lateral Sclerosis (ALS). With few effective options available, our focus is on identifying delivery methods that may enhance safety, tolerability, and clinical utility.
Weight Loss Program
Our team is exploring a repurposed compound with known metabolic activity as a potential intervention for obesity. Current efforts are centered on assessing optimal dosing, delivery format, and long-term tolerability to support future development as a scalable weight management solution.
Opioid Use Disorder Program
In response to the ongoing opioid crisis, we are investigating a compound with potential to support withdrawal management and reduce dependence. Our evaluation includes delivery strategies, access considerations, and integration into real-world treatment pathways.
The Bigger Picture
Our pipeline isn’t built on volume—it’s built on impact. Every program we pursue is guided by real-world care gaps and the potential to make a meaningful difference. Whether through partnerships, licensing, or internal development, our goal remains the same: to deliver quality therapy for life.
How We Prioritize Candidates
We evaluate potential pipeline programs using four key criteria—ensuring our development efforts remain grounded in science, scalable in practice, and centered on real patient needs.
Unmet Clinical Need
Established Safety and Pharmacology Data
Regulatory Acceleration Potential
Feasibility of Delivery Innovation